D iabetes mellitus is the leading cause of endstage renal disease (ESRD) in the United States. 1 In addition, diabetes is associated with high risks of cardiovascular morbidity and mortality that are greatly increased in the presence of chronic kidney disease (CKD). 2 The Kidney Disease Out-comes Quality Initiative (KDOQI) clinical practice guidelines and recommendations for diabetes and CKD were introduced by the National Kidney Foundation (NKF) in 2007. 2 Since publication of these guidelines, the body of evidence has evolved. Thus, the NKF convened a work group to update portions of their guideline potentially affected by the new evidence.
To inform the work of the KDOQI guideline work group, we conducted a systematic review to determine whether clinical and intermediate outcomes in patients with diabetes (type 1 or 2) and CKD were improved by intensive glycemic control, treatment of dyslipidemia, and use of agents to prevent or slow the progression of elevated albuminuria in patients with controlled blood pressure. The key questions defined by the NKF work group were:
1. In patients with diabetes (type 1 or 2), with or without CKD, does intensive glycemic control improve outcomes compared to conventional glycemic control? What harms result from intensive glycemic control?
2. In patients with diabetes (type 1 or 2) and CKD, what evidence is there that specific lipid management targets (defined as goals for total cholesterol, lowdensity lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, and triglyceride levels) or specific lipid-altering agents improve outcomes? What harms result from lipid management or use of specific lipid-altering agents?
3. What interventions prevent incident albuminuria and/or progression of albuminuria in patients with diabetes mellitus for whom a further reduction in blood pressure is not the primary clinical goal?
This report constitutes a summary of an evidence review commissioned by the NKF as the background material for the update of the KDOQI guidelines for diabetes and CKD. 3
METHODS

Overview
In consultation with the NKF-KDOQI diabetes and CKD work group, we developed and followed a standard protocol for all steps of the review process. A full technical report provides the analytic Suggested by Expert Workgroup (n=2) (Shichiri, 1995 ; UKPDS (33) 1998) framework, detailed literature search strategies, and results for the original key questions (Item S1, available as online supplementary material).
Data Sources and Study Selection
We searched MEDLINE database citations from January 2003 to October 2010 to identify randomized controlled trials that provide evidence about treatments of hyperglycemia, hyperlipidemia, and albuminuria in patients with diabetes focusing on studies published since release of the initial guidelines published in 2007 (search strategy provided as Item S2). 2 All titles and abstracts were assessed for eligibility based on specific inclusion and exclusion criteria. We also searched published reference lists, reviews, and meta-analyses. We elicited trials from the work group members including any relevant randomized controlled trials published in non-English language.
For intensive glycemic control, we included randomized controlled trials of a minimum 12 months' duration, published in English, and that enrolled individuals with type 1 or 2 diabetes (regardless of age), with or without CKD. We required studies to evaluate an intervention that significantly (ie, P Ͻ 0.05) decreased average levels of glycated hemoglobin (HbA 1c ). This report focuses on 5 trials specifically designed to compare intensive glycemic control to conventional glycemic control, although target levels of glycemic control in both the intervention and control care differed across studies.
General inclusion criteria for studies that assessed interventions aimed at lipid management were identical to the intensive glyce-mic control inclusion criteria, except they required participants to have both diabetes and CKD (of any stage). Included trials compared lipid-altering therapies that might affect LDL cholesterol, HDL cholesterol, triglyceride, or total cholesterol levels with usual practice or use of another lipid-altering agent, a different dose of the same agent, or placebo.
For management of albuminuria in normotensive patients with diabetes, we required individuals to have a mean baseline blood pressure Ͻ140/90 mm Hg with or without treatment. Treatments that could further decrease blood pressure were included. Studies in which albuminuria was a secondary end point or reported as a subgroup analysis also were considered.
Data Extraction and Assessment of Methodological Quality of Individual Studies
One investigator extracted data from each study report, including sample characteristics, interventions, and outcomes (P.F., glycemia; J.T., hyperlipidemia; and T.R., albuminuria), and a second investigator verified the extraction (Y.S., R.M., and A.I., respectively). Study quality (risk of bias) was classified as good, fair, or poor according to criteria of the Cochrane Collaboration, including allocation and concealment of treatments, use of the intention-totreat principle for data analysis, and reporting of withdrawals (number and reasons) in each study group. 4
Data Synthesis and Analysis
Our primary outcome was all-cause mortality. Secondary clinical outcomes included death from cardiovascular causes, ESRD, , and congestive heart failure), composite vascular outcomes, clinically significant retinopathy including vision loss, and symptomatic hypoglycemia that required assistance of another person. Other outcomes included in this report included changes in level of albuminuria, glomerular filtration rate (GFR), and doubling of serum creatinine concentration. When possible, given varying outcome measures and heterogeneity between studies, outcome data were pooled and analyzed in Review Manager 5.0 5 using a random-effects model. A random effects model was constructed following the methods of DerSimonian and Laird. 6 This method incorporates the heterogeneity of effects in the analysis of the overall treatment efficacy. We rated the overall strength of evidence using methodology developed by the Agency for Healthcare Research and Quality and the Effective Health Care Program. 7 The strength of the evidence was evaluated based on 4 required domains: (1) risk of bias, (2) consistency, (3) directness, and (4) precision. High strength of evidence indicates high confidence that the evidence reflects the true effect and that future research is unlikely to change our confidence in the estimate of effect. Moderate strength of evidence indicates moderate confidence that the evidence reflects the true effect and that future research may change our confidence in the estimate of effect and may change the estimate. Low strength of evidence indicates low confidence that the evidence reflects the true effect and that future research likely will change our confidence in the estimate of effect and change the estimate. Insufficient denotes that the evidence is unavailable or does not permit a conclusion. 7
RESULTS
Glycemic Control in Diabetes
We included 5 trials ( Fig 1) that randomly assigned 27,159 (range, 110-11,140) individuals with type 2 diabetes with or without CKD to intensive glycemic control versus conventional glycemic control and followed them up prospectively for micro-and macrovascular outcomes. [8] [9] [10] [11] [12] [13] Definitions of intensive glycemic control and conventional glycemic control varied (Table 1) . Study duration ranged from 3.4-10 years. Mean age of participants ranged from 49-66 years, of whom 32%-40% had a history of cardiovascular disease. Duration of diabetes ranged from 0-11.5 years, and baseline HbA 1c level ranged from 7.1%-9.4%. [8] [9] [10] [11] [12] [13] Percentages of individuals with CKD were not reported. Reporting of outcomes varied considerably across studies. Mean achieved HbA 1c level in the intensive treatment arm was 6.6% compared with 7.4% with conventional care. [8] [9] [10] [11] 13 Three studies reported median HbA 1c levels (see Table S1 ). Intensive glycemic control did not improve most clinical outcomes, including all-cause (risk ratio [RR], 1.03; 95% confidence interval [CI], 0.90-1.19) or cardiovascular (RR, 1.10; 95% CI, 0.77-1.57) mortality, fatal MI (RR, 1.01; 95% CI, 0.81-1.25), fatal (RR, 1.11; 95% CI, 0.71-1.75) and nonfa- tal (RR, 1.02; 95% CI, 0.89-1.18) stroke, or ESRD (RR, 0.87; 95% CI, 0.70-1.09; Table S2 ; Table 2 ; moderate-to high-strength evidence). Intensive glycemic control led to a small absolute reduction in nonfatal MI compared to conventional glycemic control (RR, 0.85; 95% CI, 0.76-0.95; 0.3% absolute risk reduction). These outcomes were not reported according to CKD status. Intensive glycemic control reduced the risk of new-onset micro-and macroalbuminuria, but did not alter the risk of doubling of serum creatinine level (Fig 2) .
Intensive glycemic control resulted in a 2.5-fold increased risk of severe hypoglycemia compared to conventional glycemic control (9.1% vs 3.2%; RR, 2.54; 95% CI, 1.75-3.69; n ϭ 23,182).
Management of Dyslipidemia in Diabetes and CKD
Four trials randomly assigned participants to statin (HMG-CoA [3-hydroxy-3-methylglutaryl coenzyme A] reductase inhibitor) therapy versus control and one trial randomly assigned participants to high-dose versus low-dose statin and reported relevant outcomes for patients with diabetes and CKD ( Fig 3; ( Table 4 ). Mean baseline LDL cholesterol levels ranged from 96.3-140 mg/dL (Table 3) . Study duration ranged from 3.9-5.4 years. Statins did not decrease all-cause mortality or stroke in participants with diabetes and CKD (Fig 4; Table 4 ; Table S3 ). The strength of evidence was low. We found insufficient evidence to judge the efficacy of statins for other clinical cardiovascular and kidney outcomes. Statin therapy increased regression of microalbuminuria to normoalbuminuria, but did not attenuate the decrease in estimated GFR (eGFR) in patients with baseline albuminuria. 15 High-dose statin therapy did not decrease all-cause mortality, stroke, or the risk of major cardiovascular events compared to lower dose statin therapy in participants with diabetes and CKD ( Fig 4; Table S3 ; Table 4 ). 18 Three trials randomly assigned participants with ESRD and diabetes (n ϭ 2,382; range, 396-1,255) to statin therapy versus placebo. [19] [20] [21] Two trials recruited patients with diabetes on hemodialysis therapy (n ϭ 1,986), 19, 20 and one trial recruited patients after kidney transplantation (n ϭ 396; Table 5 ). 21 For adults with diabetes of long duration (mean, 18 years from diagnosis), ESRD, and mean baseline LDL cholesterol concentration of 126 mg/dL, LDL cholesterol lowering with statins did not decrease all-cause mortality and increased the risk of fatal stroke compared to placebo ( Fig 4; Table 4 ; Table S3 ; moderate-strength evidence). LDL cholesterol lowering with statins did not reduce the risk of other cardiovascular outcomes compared to placebo (Table  S3 ; low-strength evidence). There were no differences in serious adverse events in the statin and placebo arms.
Three trials randomly assigned participants with diabetes and CKD to a fibrate versus placebo (Table  6 ). [22] [23] [24] Only one trial reported one composite clinical outcome for this subgroup. In men with diabetes, coronary artery disease, and CKD (defined by eGFR), gemfibrozil treatment significantly reduced the risk of the composite outcome of fatal coronary heart disease, nonfatal MI, and stroke compared to placebo. 22 In patients with diabetes and microalbuminuria, fenofibrate did not reduce the risk of progression from Table  4 ; Table S3 ). 23, 24 None of the trials reported adverse events or withdrawals for the subgroup of participants with CKD and diabetes.
Management of Albuminuria in Normotensive Patients With Diabetes
In addition to the treatments to control hyperglycemia and hyperlipidemia described, 10 studies from 2006-2011 reported information about the effects of treatments for albuminuria in patients with diabetes for whom blood pressure control was not a goal of therapy ( Fig 5) . [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Baseline patient characteristics from these studies are listed in Table 7 . The effects of angiotensin II receptor blockers on the incidence of microalbuminuria during several years of follow-up were inconsistent (Table 8 ). Haller et al 28 reported a small but significant reduction in the incidence of microalbuminuria, Bilous et al 33 did not find a significant effect on the incidence of microalbuminuria or urinary albumin excretion rate, and Mauer et al 27 reported an increased incidence of microalbuminuria and urinary albumin excretion rate. The latter study also did not find a significant effect of enalapril on these outcomes. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) study group ran- (Continued) domly assigned patients to different blood pressure targets (140 vs 120 mm Hg systolic) and used a number of different medications to reduce systolic blood pressures to the lower target of 120 mm Hg in the intensively treated group. In those randomly assigned to the low target blood pressure, there was no significant effect on incidence of microalbuminuria, but there was a small decrease in incidence of macroalbuminuria and median urinary albumin-creatinine ratio. 32 Makino et al 35, 44 found a significant decrease in urinary albumin-creatinine ratio, progression to macroalbuminuria, and regression to normoalbuminuria when participants with microalbuminuria at baseline were treated with an angiotensin II receptor blocker. None of these studies provided high-quality evidence that the observed effects of the treatments on albuminuria, or lack thereof, were translated into effects on clinical cardiovascular or kidney outcomes. Treatment of patients with diabetes and high amounts of proteinuria with folic acid and high doses of vitamins B 6 and B 12 in one modest-sized study did not decrease proteinuria and adversely affected cardiovascular outcomes. 25 
DISCUSSION
Glycemic Control in Diabetes
For adults with type 2 diabetes, intensive glycemic control (mean achieved HbA 1c level of 6.6%) did not improve clinical outcomes, with the exception of nonfatal MI, compared to conventional glycemic control (mean HbA 1c , 7.4%) through a mean follow-up of 6.7 years. Intensive glycemic control also resulted in increased severe hypoglycemia. Most studies excluded participants with moderate kidney disease (serum creatinine Ͼ1.5 mg/dL, mean baseline serum creatinine Յ1 mg/dL in all studies) and did not report clinical outcomes stratified by CKD status. Intensive glycemic control decreased incident microalbuminuria and new-onset macroalbuminuria. However, the clinical importance of improvements in micro-and macroalbuminuria is not clear given the lack of longterm benefits on patient-centered outcomes and demonstrated harms from intensive glycemic control.
Despite heterogeneity in baseline characteristics of participants and glycemic target goals, the trials' results are consistent: intensive glycemic control to HbA 1c levels Յ7% did not improve clinical outcomes and resulted in greater risk of severe hypoglycemia compared to less intensive control. These results need to be placed into context with the findings of the long-term follow-up of the UKPDS (United Kingdom Prospective Diabetes Study) cohort. The original UK-PDS findings determined that more intensive glycemic control (HbA 1c ϭ 7.0% vs 7.9%) over 10 years of follow-up in newly diagnosed patients resulted in a relative 12% risk reduction of any diabetes-related end point. 8 However, this reduction was driven primarily by a 25% reduction in microvascular end points, but not in reduction of mortality or clinical cardiovascular or kidney outcomes. 8, 36 After an additional 10 years of postintervention follow-up, despite loss of differences in mean HbA 1c levels between the arms by 1 year (mean HbA 1c ϭ 8.1% in both arms), the UKPDS authors observed a small (2.5-4.1/1,000 patient-years) absolute risk reduction for diabetic and cardiovascular end points in the intensive control group compared to usual care that was of marginal statistical significance given the multiple analyses performed. 36 The discrepancy in the findings of the on-treatment and prospective cohort studies can either be spurious or be explained by a "legacy effect," a delayed benefit of strict glycemic control for clinical outcomes after the difference in glycemic control disappears.
A legacy effect was observed in the DCCT (Diabetes Control and Complications Trial) in patients with type 1 diabetes. The DCCT/EDIC (Epidemiology of Diabetes Interventions and Complications) study group observed delayed benefits of strict glycemic control in type 1 diabetes: after 17 years of follow-up, despite narrowed difference in HbA 1c levels between trial arms (8.0% in the intensive group compared to 8.2% in the conventional group), intensive treatment was associated with a 42% reduction in risk of a first cardiovascular event (95% CI, 9%-63%; P ϭ 0.02) and a 57% reduction in risk of nonfatal MI, stroke, or cardiovascular disease death (95% CI, 12%-79%; P ϭ 0.02) compared to the conventional control group. 37 After 22 years of follow-up, intensive therapy reduced the risk of decreased eGFR (Ͻ60 mL/min/1.73 m 2 ) by 50% (95% CI, 18%-69%; P ϭ 0.006). 38 The magnitude of the potential delayed benefit needs to be weighed against the earlier more frequent harm of severe hypoglycemia. 
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Total events Heterogeneity: Not applicable Test for overall effect: Z = 0.83 (P = 0.41) Although the optimal target HbA 1c level remains to be determined in adults with type 2 diabetes, current evidence indicates that in patients with type 2 diabetes, glycemic management to achieve an HbA 1c level Ͻ7% does not improve clinical outcomes for at least 10 years compared to HbA 1c level of approximately 8%-8.5%. Although many individuals enrolled in these trials were older and had fairly long-standing diabetes and coexisting cardiovascular disease, they are representative of individuals with type 2 diabetes currently managed in clinical practice. Future research should address optimal HbA 1c levels in adults with type 2 diabetes and CKD, specifically in younger more recently diagnosed patients with few comorbid conditions. Additionally, future research is needed to evaluate the effectiveness and harms of newer glycemic control medications in patients with CKD.
High-dose statin versus low-dose statin
Management of Dyslipidemia in Diabetes and CKD
HMG-CoA Reductase Inhibitors in CKD
In adults with diabetes and CKD defined by decreased eGFR, with or without a history of coronary artery disease, treatment with HMG-CoA reductase inhibitors did not decrease all-cause mortality and stroke compared to placebo. The strength of evidence for these outcomes was low and insufficient for other relevant clinical outcomes. These results should be interpreted with caution because they are based on subgroup or post hoc analyses of larger trials that were not designed to evaluate the effect of statins on cardiovascular outcomes in patients with diabetes and CKD. Our summary analyses included only the few studies that reported outcomes for the subgroup of interest.
Several studies evaluated the effect of LDL cholesterol lowering in patients with either diabetes or CKD, individually, for prevention of cardiovascular outcomes. These studies suggest a benefit of lipidlowering medications for primary and secondary prevention of cardiovascular events. 14, [34] [35] [36] [37] [39] [40] [41] Subgroup analysis of the individual patient-level meta-analysis of 14 randomized controlled trials of statins showed a 17% relative reduction per 1-mmol/L decrease in LDL cholesterol level for major vascular events, defined as the composite outcome of MI, coronary death, stroke, or coronary revascularization in patients with diabetes and eGFR Ͻ60 mL/min/1.73 m 2 . 40 Most recently, results of SHARP (Study of Heart and Renal Protection), which randomly assigned participants with CKD to the combination of simvastatin (20 mg)-ezetimibe (10 mg) or placebo, were published, but because of timing of the publication were not included in this systematic review and analyses. 42 The simvastatin-alone arm was re-randomly assigned to the simvastatin-ezetimabe and placebo arms early in the trial, making it impossible to determine whether the addition of ezetimibe to simvastatin offers a safety or efficacy advantage over simvastatin alone. Results support that LDL cholesterol lowering (achieved difference of 32 mg/dL) reduces by 22% in relative terms major atherosclerotic events (defined as nonfatal MI, any cardiac death, nonhemorrhagic stroke, or arterial revascularization excluding dialysis access), but not individual outcomes of all-cause mortality or ESRD, in patients with CKD and diabetes. 42
HMG-CoA Reductase Inhibitors in ESRD
In patients with ESRD on dialysis therapy and with diabetes, we found evidence of moderate strength that LDL cholesterol lowering with statins did not reduce all-cause mortality after follow-up of 4 years compared with placebo. Our conclusions are based primarily on 4D (Die Deutsche Diabetes Dialyse Studie), 20 which was included in the 2007 guideline update. Since 2007, another large randomized controlled trial primarily in patients without diabetes but receiving dialysis supported the findings of 4D. In this post hoc analysis in patients with diabetes, being assigned to rosuvastatin treatment was associated with a nonsignificant 16% decrease in the composite outcome of cardiac death, nonfatal MI, or fatal and nonfatal stroke; a significant 32% decrease in the risk of cardiac death or nonfatal MI; and a significant 5-fold increase in the risk of hemorrhagic stroke. 18, 45 SHARP included 3,023 patients with and without diabetes who were receiving maintenance dialysis at baseline. 42 In participants with ESRD, a statinezetimibe combination did not reduce the risk of a major atherosclerotic event compared to placebo. In 496 participants on peritoneal dialysis therapy, simvastatin-ezetimibe combination resulted in a nonsignificant 30% relative reduction in risk of a major atherosclerotic event. 42 Summary of data from the 4 listed trials in patients on kidney replacement therapy reported in the SHARP publication suggest that patients allocated to LDL cholesterol reduction arms were 17% less likely to have nonfatal MI and 26% less likely to undergo coronary revascularization than patients allocated to placebo, whereas their risks of nonfatal stroke and cardiovascular death did not differ. 42 Results were not reported separately for patients with diabetes and ESRD. 42 Current evidence does not support initiation of statin therapy in patients with ESRD treated by dialysis for primary or secondary prevention of all-cause or cardiovascular mortality.
Fibrates in Diabetes and CKD
The current evidence is insufficient to determine the effect of fibrates on cardiovascular and clinical kidney outcome prevention in patients with diabetes and CKD. A single study, VA-HIT (Veterans Affairs Cooperative HDL Cholesterol Intervention Trial), reported results for only a composite vascular outcome in a small subgroup of participants with diabetes and CKD. 22 In patients with diabetes and albuminuria, fenofibrate treatment increased regression from micro-to normoalbuminuria and from macro-to microalbuminuria compared to placebo.
Future research is needed to establish target LDL cholesterol levels for primary and secondary prevention of cardiovascular events in patients with diabetes and CKD and examine the effect of lipid-altering agents on clinical kidney outcomes such as ESRD and death related to kidney failure, as well as kidney relevant laboratory measures such as albuminuria and eGFR.
Management of Albuminuria in Normotensive Patients With Diabetes
Treatment with angiotensin II receptor blockers for several years does not substantially or consistently reduce the incidence of microalbuminuria in patients with controlled blood pressure. Progression of existing microalbuminuria was decreased in one study. The reviewed evidence was not sufficient to determine whether any of these effects on albuminuria, or lack thereof, led to effects on major cardiovascular or kidney outcomes. Large and prolonged studies are needed to provide conclusive evidence of whether the effects of treatments on albuminuria per se eventually will translate to improvements in clinical cardiovascular disease and kidney outcomes. The use of albuminuria as a surrogate marker of benefit of an intervention in diabetic kidney disease was the subject of joint US Food and Drug Administration and NKF symposium in 2008. 43 This conference concluded that the evidence was insufficient to use changes in albuminuria as a surrogate measure for clinical outcomes in patients with diabetes. This evidence review supports that conclusion. Whether and how to manage albuminuria in patients with diabetes for whom hyperglycemia, hyperlipidemia, and blood pressure are adequately controlled remains an unanswered question. Future trials should incorporate several consecutive measurements of urine albumin excretion to define albuminuria, establish a treatment washout phase to determine durability of effect on albuminuria, and include clinical cardiovascular and kidney outcomes.
Limitations
The evidence incorporated into this systematic review had several limitations. Reports published in non-English language were excluded. There are important variations among studies with respect to HbA 1c treatment goals and duration and type of interventions used to control hyperglycemia. Glycemic control trials did not report clinical outcomes according to CKD status. Most of the evidence was obtained in older participants, many with concomitant medical conditions and diabetes of many years' duration. While limiting generalizability to younger patients with diabetes and those with shorter duration or fewer comorbid conditions, the findings from published studies are representative of a large majority of patients with diabetes and reflect clinical practice. Data are limited regarding lipid and albuminuria management to mostly post hoc analyses of randomized controlled trials not designed to evaluate interventions in patients with diabetes and CKD. Follow-up duration, although many years, may still be too short to assess infrequent clinical outcomes and adverse events that might require decades to accrue. Nonetheless, the present findings provide the most solid evidence to guide the clinical management of patients with type 2 diabetes and CKD. 
Treatment Effects in Intervention vs Control Groups Study Quality
Estacio et al, 34 2006 Intervention (n ϭ 66): intensive BP control to target DBP of 75 mm Hg, with valsartan 80-160 mg/d (79%), then HCTZ (15%) and metoprolol (3%), in stepwise manner Control (n ϭ 63): moderate BP control to maintain DBP 80-90 mm Hg (and SBP Ͻ140); 75% achieved with placebo only; the rest needed step treatment: valsartan (25%) and HCTZ (5%) Achieved BP: Mean during F/U of 118/75 (intervention) and 124/80 (control) F/U: 1.9 y (mean) ⌬UAER in those with normal albuminuria at baseline and followed up for 2 y: 6.9 g/ min at baseline to 4.4 g/min (n ϭ 28) in intervention group, 4.9 g/min at baseline to 7.8 g/min (n ϭ 24) in control group Baseline-adjusted geometric mean of UAER difference at 2 y: 1.1 g/min; P ϭ 0.02 Transition to macroalbuminuria: BP subgroup 1: 10% (intervention 1) vs 33% (control); P Ͻ 0.01 BP subgroup 1: 12% (intervention 2) vs 33% (control); P Ͻ 0.01 BP subgroup 2: 11% (intervention 1) vs 34% (control); P Ͻ 0.01 BP subgroup 2: 15% (intervention 2) vs 34% (control); P Ͻ 0.01 Transition to normoalbuminuria: BP subgroup 1: 20% (intervention 1) vs 2% (control); P Ͻ 0.01 BP subgroup 1: 16% (intervention 2) vs 2% (control); PϽ0.01 BP subgroup 2: 21% (intervention 1) vs 1% (control); PϽ0.01 BP subgroup 2: 12% (intervention 2) vs 1% (control); P Ͻ 0.01 ⌬UACR:
BP subgroup 1: Ϫ67 mg/g (intervention 1) vs ϩ88 mg/g (control); P Ͻ 0.01 BP subgroup 1: Ϫ84 mg/g (intervention 2) vs ϩ88 mg/g (control); P Ͻ 0.01 BP subgroup 2: Ϫ65 mg/g (intervention 1) vs ϩ115 mg/g (control); P Ͻ 0.01 BP subgroup 2: Ϫ82 mg/g (intervention 2) vs ϩ115 mg/g (control); P Ͻ 0.01
Allocation concealment: unclear Blinding: double ITT analysis: no, 13 excluded from primary analysis Withdrawals described:
yes Overall study rating: fair Mann et al, 26 2008 (ONTARGET) N ϭ 9,612 with DM (37% of 25,620 randomized) Intervention 1 (n ϭ 8,576; 3,146 with DM): ramipril 10 mg/d Intervention 2 (n ϭ 8,542; 3,246 with DM): telmisartan 80 mg/d Intervention 3 (n ϭ 8,502; 3,220 with DM): ramipril and telmisartan combination F/U: 4.7 y (median) Composite of dialysis, doubling of SCr, or death in subgroup with DM: 17.0% (intervention 1); HR, 1.0 (95% CI, 0.9-1.1) a for intervention 2 (NS); HR, 1.1 (95% CI, 0.95-1.20) a for intervention 3 (NS) Composite of CV death, nonfatal MI or stroke or hospital admission for HF in subgroup with DM: 20.7% (intervention 1); HR, 1.0 (95% CI, 0.9-1.1) a for intervention 2 (NS); HR, 0.9 (95% CI, 0.8-1.1) a for intervention 3 (NS) 
Conclusions
Intensive glycemic control in patients with type 2 diabetes mellitus does not decrease clinical cardiovascular and renal outcomes and increases the risk of severe hypoglycemia. Statin therapy is not effective for reducing all-cause mortality or stroke in individuals with type 2 diabetes and CKD, although the strength of evidence is low. Angiotensin II receptor blockers do not substantially decrease the incidence of microalbuminuria in patients with diabetes and controlled blood pressure. Evidence was insufficient to determine whether the effects of treatments on albuminuria led to eventual effects on clinical outcomes. Overall, more intensive clinical management of patients with diabetes and CKD has little to no clinical benefit through approximately 10 years of follow-up, but results in harms. This information should be considered when formulating treatment strategies for individual patients.
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